Drugs / EVETIFATOR
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06281158 | Mar → Apr 2024 | — | Denali Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05006352 | Aug 2021 → Dec 2022 | amyotrophic lateral sclerosis | Denali Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04581772 | Dec 2020 → Jun 2021 | — | Denali Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04268784 | Feb 2020 → Aug 2021 | — | Denali Therapeutics Inc. | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT05842941 | May 2023 → Oct 2024 | amyotrophic lateral sclerosis | Merit E. Cudkowicz, MD | Completed | No outcome recorded |
| Phase 2/3 | NCT04297683 | Jun 2020 → Jul 2027 expected | amyotrophic lateral sclerosis | Merit E. Cudkowicz, MD | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EVETIFATOR | ChEMBL registry synonym — accepted as the source's own label CHEMBL5569312 ↗ |
| Known as | DNL343 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04297683 ↗ |
| Modality | Small molecule | — CHEMBL5569312 ↗ |
| Route | Oral | “Single and repeating oral dose(s)” NCT04268784 ↗ |